JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on TRVI stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee’s rating is based on the promising data from Trevi Therapeutics’ Haduvio trials, particularly the Phase 2b CORAL trial for idiopathic pulmonary fibrosis (IPF). The trial results showed that while gastrointestinal and central nervous system side effects were common, they were mostly mild, and the discontinuation rates were lower than in previous trials, indicating effective mitigation strategies. This suggests that patients are able to tolerate the drug due to its benefits.
Furthermore, the dose-response data from the trials indicate a broad therapeutic range, allowing for flexibility in dosing which could optimize risk-benefit if approved. The potential for Haduvio to address the unmet needs of IPF patients with intractable cough, along with upcoming data and trials in non-IPF interstitial lung disease, represents significant opportunities for Trevi. These factors, combined with the market’s misunderstanding of Haduvio’s risk-benefit profile, contribute to the Buy rating.
In another report released today, Needham also maintained a Buy rating on the stock with a $24.00 price target.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TRVI in relation to earlier this year.